Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A Pharmacokinetic and Pharmacogenetic Analysis.

Marano M, Serafinelli J, Cairoli S, Martinelli D, Pisani M, Palumbo G, Cefalo MG, Cecchetti C, Di Nardo M, Falvella FS, Goffredo BM.

Ther Drug Monit. 2018 Aug;40(4):386-388. doi: 10.1097/FTD.0000000000000522.

PMID:
29683873
2.

Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.

Gao Y, Gong M, Zhang C, Kong X, Ma Y.

Medicine (Baltimore). 2017 Oct;96(43):e8337. doi: 10.1097/MD.0000000000008337.

3.

Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.

Garnock-Jones KP.

Drugs. 2011 Jul 9;71(10):1333-53. doi: 10.2165/11207390-000000000-00000. Review.

PMID:
21770480
4.

Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.

Garnock-Jones KP.

BioDrugs. 2011 Dec 1;25(6):401-4. doi: 10.2165/11207620-000000000-00000. Review.

PMID:
22050343
5.

Eltrombopag: a novel oral thrombopoietin receptor agonist.

Corman SL, Mohammad RA.

Ann Pharmacother. 2010 Jun;44(6):1072-9. doi: 10.1345/aph.1P042. Epub 2010 May 11. Review. Erratum in: Ann Pharmacother. 2010 Jul-Aug;44(7-8):1352-3.

PMID:
20460556
6.

Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.

Zhang Y, Kolesar JM.

Clin Ther. 2011 Nov;33(11):1560-76. doi: 10.1016/j.clinthera.2011.10.004. Epub 2011 Nov 4. Review.

PMID:
22054810
7.

Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).

Boyers D, Jia X, Crowther M, Jenkinson D, Fraser C, Mowatt G.

Health Technol Assess. 2011 May;15 Suppl 1:23-32. doi: 10.3310/hta15suppl1/03. Review.

8.

Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.

Chouhan JD, Herrington JD.

Pharmacotherapy. 2010 Jul;30(7):666-83. doi: 10.1592/phco.30.7.666. Review.

PMID:
20575632
9.
10.

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M.

Lancet. 2009 Feb 21;373(9664):641-8. doi: 10.1016/S0140-6736(09)60402-5.

PMID:
19231632
11.

Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.

Tarantino MD, Fogarty PF, Shah P, Brainsky A.

Platelets. 2015;26(1):93-6. doi: 10.3109/09537104.2013.870333. Epub 2014 Jan 16.

PMID:
24433306
12.

A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.

Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, Ikeda Y, Hattori T, Katsura K, Kanakura Y.

J Thromb Haemost. 2012 May;10(5):799-806. doi: 10.1111/j.1538-7836.2012.04695.x.

13.
14.

Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.

Burness CB, Keating GM, Garnock-Jones KP.

Drugs. 2016 May;76(8):869-78. doi: 10.1007/s40265-016-0581-4. Review.

PMID:
27151255
15.

Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.

Kühne T, Imbach P.

Ann Hematol. 2010 Jul;89 Suppl 1:67-74. Epub 2010 Apr 20. Review.

PMID:
20405290
16.

Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.

Maroun MC, Ososki R, Andersen JC, Dhar JP.

Lupus. 2015 Jun;24(7):746-50. doi: 10.1177/0961203314559632. Epub 2014 Nov 21.

PMID:
25416695
17.

Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.

González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Pérez-Rus G, Hernández-Rivas JA, Bernat S, Bastida JM, Martínez-Badas MP, Martínez-Robles V, Soto I, Olivera P, Bolaños E, Alonso R, Entrena L, Gómez-Nuñez M, Alonso A, Yera Cobo M, Caparrós I, Tenorio M, Arrieta-Cerdán E, Lopez-Ansoar E, García-Frade J, González-Porras JR.

Br J Haematol. 2017 Sep;178(6):959-970. doi: 10.1111/bjh.14788. Epub 2017 Jun 1.

PMID:
28573819
18.

Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.

Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.

J Clin Pharm Ther. 2012 Dec;37(6):729-32. doi: 10.1111/j.1365-2710.2012.01353.x. Epub 2012 May 14.

PMID:
22583038
19.

Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.

Wang XL, Li AM.

Blood Coagul Fibrinolysis. 2016 Oct;27(7):825-827. Review.

PMID:
26650460
20.

Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP.

Mori M, Kato M, Koh K, Hanada R.

Rinsho Ketsueki. 2015 May;56(5):511-3. doi: 10.11406/rinketsu.56.511. Japanese.

PMID:
26062675

Supplemental Content

Support Center